Colonic mucosal diffuse congestion associated with Osimertinib

Abstract

Introduction

Non-small cell lung cancer (NSCLC) is the most common histological subtype of lung cancer. Osimertinib has been recommended as first-line treatment of advanced NSCLC with EGFR mutations. Previous studies have only reported cases of gastrointestinal bleeding due to Erlotinib and gefitinib, but to date, always no cases of gastrointestinal bleeding due to Osimertinib have been reported.

Case Report

We report a case of a female patient with NSCLC with EFGR mutation. After 1.5 years of treatment with Osimertinib, a colonoscopy showed diffuse congestion of the colonic mucosa.

Management and Outcome

The patient’s symptoms of blood in the stool disappeared, after stopping Osimertinib and giving mucosal protection treatment for 1 week.

Discussion

Osimertinib may have contributed to gastrointestinal bleeding because no recurrent bleeding was observed after discontinuation of treatment. Physicians and patients should be aware that osimertinib may increase the risk of gastrointestinal bleeding.

Keywords

Lung cancer EGFR mutation Osimertinib case report

Get full access to this article

View all access options for this article.

References

Siegal

Miller

Jemal

. Cancer statistics, 2012. CA Cancer J Clin 2014; 64: 9–29.

Testa

Castelli

Pelosi

. Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers (Basel) 2018; 10: 248.

Cross

Ashton

Ghiorghiu

, et al. AZD9291, An irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer novel mutant-selective EGFR inhibitor overcomes drug resistance. Cancer Discov 2014; 4: 1046–1061.

Malapelle

Ricciuti

Baglivo

, et al. Osimertinib. Small Mol Oncol 2018; 211: 257–276. doi:10.1007/978-3-319-91442-8_18

Goss

Tsai

C-M

Shepherd

, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016; 17: 1643–1652.

Yang

Ahn

Kim

, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 2017; 35: 1288–1296.

Soria

J-C

Ohe

Vansteenkiste

, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med 2018; 378: 113–125.

Xie

Wang

, et al. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol 2022; 15: 1–32.

Mok

Y-L

Ahn

M-J

, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–640.

10.

Saeki

Nishimatsu

Ihara

, et al. Osimertinib-induced unilateral diffuse alveolar hemorrhage in a patient with pulmonary adenocarcinoma. J Med Cases 2021; 12: 295.

11.

Forte

Sangani

. Emerging risk profile of lung cancer therapy: diffuse alveolar hemorrhage from osimertinib. Case Rep Oncol Med, 2019; 2019. doi:10.1155/2019/6185943

12.

Hayasaka

Shiono

Yanagawa

, et al. Hemorrhage of a pancreatic metastasis from lung adenocarcinoma after osimertinib therapy. J Thorac Dis 2018; 10: E686–E6E9.

13.

Bai

Liu

Shi

, et al. Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding. Pak J Med Sci 2013; 29: 1278.

14.

Olayioye

Neve

Lane

, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159–3167.

15.

Komori

Morimoto

Date

, et al. A case of suspected alveolar hemorrhage due to osimertinib. Lung Cancer 2019; 59: 366–371.

16.

Hayasaka

Shiono

Yanagawa

, et al. Hemorrhage of a pancreatic metastasis from lung adenocarcinoma after osimertinib therapy. J Thorac Dis 2018; 10: E686.